A Comparison of Long-acting Injectable Medications for Schizophrenia
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to compare the "real-world" effectiveness of two
FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone
palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective
disorder who are expected to benefit from the improved medication compliance associated with
injectable medications. The goal is to evaluate the effects of the medications on outcomes of
importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy
makers (all of the above plus costs).
Phase:
Phase 4
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborators:
Duke University National Institute of Mental Health (NIMH) University of North Carolina, Chapel Hill